Kinza Bakht

Kinza Bakht

Auto-generated profile, based on publicly available information

Kinza Bakht

Sheikh Zayed Medical College, Rahim Yar Khan, Punjab, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in Medicine
Verified
Journal Article
Open access
MQMuhammad Ahmad Qureshi
Muhammad Ahmad Qureshi
MAMaaz Amir
Maaz Amir
DBDanyal Bakht
Danyal Bakht
KAKhawar Ali
Khawar Ali
AAAhmed Asif
Ahmed Asif
MAMuhammad Khan Buhadur Ali
Muhammad Khan Buhadur Ali
Background: Mitral valve surgery is a widely performed intervention for the treatment of various mitral valve pathologies. Postoperative conduction disturbances may necessitate permanent pacemaker (PPM) implantation. This study aims to identify and quantify patient-related, cardiovascular, procedural risk factors, and risk score-based predictors of PPM implantation following mitral valve surgery. Methods: The conduct of this systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. A systematic literature search was performed across PubMed, Cochrane Library, Google Scholar, and Embase, including studies published from inception until September 2024. Statistical analyses were conducted using RevMan 5.4 software. Results: The meta-analysis included 8 studies totaling 39,634 patients (PPM: 3417; no PPM: 36,217) and revealed multiple significant predictors of postoperative PPM implantation. Among demographics, advanced age (mean difference [MD] 3.54; P < .00001) and female sex (odds ratio [OR] 1.19; P < .00001) were found as independent risk factors. Comorbidities included hypertension (OR 1.71, P < .00001), diabetes (OR 1.96, P < .00001), renal disease (OR 1.96, P < .00001), preexisting atrial fibrillation (OR 1.82, P < .00001), prior stroke (OR 1.57, P < .00001), chronic lung disease (OR 1.38, P < .00001), peripheral vascular disease (OR 2.03, P = .01), and smoking history (OR 1.19, P < .0001). Cardiovascular predictors comprised mitral stenosis (OR 1.77, P <.00001), prior cardiac surgery (OR 1.48, P = .0002), New York Heart Association class III/IV (OR 1.38, P = .005), and New York Heart Association class I (OR 0.64, P = .03). Procedural factors showed longer cardiopulmonary bypass time (MD 9.89, P < .00001) and aortic cross-clamp duration (MD 11.96, P < .00001) increasing risk, along with concomitant atrial fibrillation ablation (OR 1.34, P = .002). Increased society of thoracic surgeons’ mortality risk (MD 1.14%, P = .04) and EuroScore (MD 2.16, P = .0005), both effectively predicted PPM need. Conclusion: This meta-analysis represents the first comprehensive evaluation of risk factors associated with PPM implantation in patients undergoing mitral valve surgery. Several significant risk factors have been identified, warranting further research to validate and expand upon these findings.

7 August 2025 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
MAMuhammad Arham
Muhammad Arham
ADAllah Dad
Allah Dad
MMMohammad Hamza Bin Abdul Malik
Mohammad Hamza Bin Abdul Malik
TSTalha Sajjad
Talha Sajjad
MMMUHAMMAD AWAIS BIN ABDUL MALIK
MUHAMMAD AWAIS BIN ABDUL MALIK
KBKinza Bakht
Kinza Bakht

19 May 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
ABAdnan Bhat
Adnan Bhat
MAMuhammad Arham
Muhammad Arham
ZAZahra Ali
Zahra Ali
SISaniya Ishtiaq
Saniya Ishtiaq
MRMuhammad Abdul Rehman
Muhammad Abdul Rehman
PDPeter V. Draganov
Peter V. Draganov

4 August 2025 in International Journal of Gastrointestinal Intervention
Verified
Journal Article
Open access
PDF file
ABAdnan Bhat
Adnan Bhat
ADAllah Dad
Allah Dad
KBKinza Bakht
Kinza Bakht
MAMuhammad Arham
Muhammad Arham
HSHumza Saeed
Humza Saeed
PDPeter Vassilev Draganov
Peter Vassilev Draganov
Adnan Bhat, Allah Dad, Kinza Bakht, Muhammad Arham, Humza Saeed, Zahra Ali, Faseeh Haider, Saniya Ishtiaq, Anchit Chauhan, Danyal Bakht, Adil Ahmed, Ali Naseem, Imran Ali Reshi, Dennis Yang, and Peter Vassilev Draganov. Int J Gastrointest Interv -0001;0:. https://doi.org/10.18528/ijgii250049

24 July 2026 in Medicine
Verified
Journal Article
Open access
DBDanyal Bakht
Danyal Bakht
MAMuhammad Arham
Muhammad Arham
FYFaiza Yousaf
Faiza Yousaf
MAMaaz Amir
Maaz Amir
MBMaha Akbar Baloch
Maha Akbar Baloch
MSMuhammad Saad
Muhammad Saad
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Antazoline, a first-generation antihistamine with antiarrhythmic properties, has shown efficacy in the rapid conversion of recent-onset AF to sinus rhythm; however, direct comparative evidence against standard antiarrhythmic agents remains limited. This study aims to systematically evaluate the efficacy and safety of antazoline for pharmacological cardioversion of AF, in comparison with standard antiarrhythmic agents such as amiodarone and propafenone. Methods: The methodology of this systematic review and meta-analysis adhered to the preferred reporting items for systematic reviews and meta-analyses guidelines. A systematic search was conducted in ScienceDirect, Embase, PubMed, and Cochrane Library from inception to April 2025, including citation and reference screening. Statistical analyses were performed using R version 2025.05.0 + 496. Results: From 172 records, 5 studies comparing antazoline with propafenone (n = 5) or amiodarone (n = 3) for AF were included. For antazoline vs propafenone, conversion to sinus rhythm favored antazoline (risk ratio [RR] 1.13 [95% confidence interval (CI): 1.04–1.23], P = .017). No significant difference was observed in time to conversion (mean difference −10.98 [95% CI: −124.93–102.98], P = .436), bradycardia (RR 0.84 [95% CI: 0.35–2.03], P = .478), hypotension (RR 0.40 [95% CI: 0.14–1.12], P = .056), or other adverse events (RR 1.24 [95% CI: 0.01–247.13], P = .694). For antazoline vs amiodarone, conversion to sinus rhythm favored antazoline (RR 1.22 [95% CI: 1.08–1.36], P = .018, I 2 = 0%), with no significant differences in bradycardia (RR 1.36 [95% CI: 0–1072357.09], P = .823) or hypotension (RR 1.05 [95% CI: 0.04–26.16], P = .877). Conclusion: Antazoline might be more effective than propafenone and amiodarone in achieving sinus rhythm in AF, with no significant differences in safety outcomes.

15 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
Samiullah ShaikhSamiullah Shaikh
Samiullah Shaikh
SSSidra Samad
Sidra Samad
KBKinza Bakht
Kinza Bakht
AMArun Maloth
Arun Maloth
ADAllah Dad
Allah Dad
ABAdnan Bhat
Adnan Bhat
Purpose: Chemotherapy-induced neutropenia (CIN) is a common complication that increases the risk of infection, hospitalization, and treatment delays. While granulocyte colony-stimulating factors (G-CSFs) like filgrastim and pegfilgrastim are used to reduce these risks, limitations in dosing schedules and variability remain. Efbemalenograstim alfa (F-627), a novel long-acting recombinant G-CSF, has emerged as a potential alternative. This systematic review and meta-analysis aimed to evaluate its comparative safety and efficacy against standard G-CSFs in patients undergoing chemotherapy for non-myeloid malignancies. Methods: A comprehensive literature search was conducted across six databases for randomised controlled trials (RCTs) comparing F-627 to standard G-CSFs. Data from three active-controlled trials were pooled using Review Manager (RevMan) 5.4.1, with results expressed as risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes. Heterogeneity was assessed using the I² statistic. Narrative synthesis was performed for the data in the placebo-controlled trial and outcomes with insufficient data for meta-analysis. Risk of bias and evidence quality were evaluated using the Cochrane RoB 2.0 tool and GRADE guidelines, respectively. Results: Four RCTs comprising 973 patients were included, with 533 receiving F-627. F-627 showed comparable efficacy to standard G-CSFs in reducing duration of Grade 4 neutropenia in cycle 1 (MD = 0.04 days; 95% CI: − 0.04 to 0.13; I² = 0%). Incidence of severe neutropenia and febrile neutropenia were also similar (RR = 1.02; 95% CI: 0.97–1.07 and RR = 1.33; 95% CI: 0.41–4.30, respectively). However, a placebo-controlled trial showed a significant reduction in neutropenia and febrile neutropenia incidence with F-627. Secondary outcomes and adverse event profiles were broadly comparable across treatment arms. Conclusion Efbemalenograstim alfa offers a comparable safety and efficacy profile to standard G-CSFs for the prevention of CIN, supporting its role as a viable therapeutic option in non-myeloid cancers.